Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Friedrich Scheiflinger

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
Blood|December 18, 2012
Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patientsShawn F J Whelan, Christoph J Hofbauer, Frank M Horling, et al.
Journal of Thrombosis and Haemostasis : JTH|January 26, 2023
Treatment with recombinant ADAMTS13, alleviates hypoxia/reoxygenation-induced pathologies in a mouse model of human sickle cell diseasePaolo Rossato, Helmut Glantschnig, Fabio Canneva, et al.
Thrombosis and Haemostasis|September 28, 2006
In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpuraRoberta Donadelli, Federica Banterla, Miriam Galbusera, et al.
Blood|May 14, 2005
ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseasesManfred Rieger, Pier Mannuccio Mannucci, Johanna A Kremer Hovinga, et al.
Blood|June 4, 2005
Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 casesFadi Fakhouri, Jean-Paul Vernant, Agnès Veyradier, et al.
Haematologica|April 21, 2022
Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell diseasePaolo Rossato, Enrica Federti, Alessandro Matte, et al.
Expert Review of Clinical Pharmacology|February 10, 2015
Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodesPeter L Turecek, Brigitt Abbühl, Srilatha D Tangada, et al.
Blood|December 18, 2014
Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humansChristoph J Hofbauer, Shawn F J Whelan, Maria Hirschler, et al.
European Journal of Pharmacology|December 24, 2017
Pharmacokinetics, disease-modifying activity, and safety of an experimental therapeutic targeting an immunological isoform of macrophage migration inhibitory factor, in rat glomerulonephritisWerner Höllriegl, Alexander Bauer, Bernhard Baumgartner, et al.
The Journal of Biological Chemistry|January 13, 2012
Neutralization of macrophage migration inhibitory factor (MIF) by fully human antibodies correlates with their specificity for the β-sheet structure of MIFRandolf J Kerschbaumer, Manfred Rieger, Dirk Völkel, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Blood|December 18, 2012
Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patientsShawn F J Whelan, Christoph J Hofbauer, Frank M Horling, et al.
Journal of Thrombosis and Haemostasis : JTH|January 26, 2023
Treatment with recombinant ADAMTS13, alleviates hypoxia/reoxygenation-induced pathologies in a mouse model of human sickle cell diseasePaolo Rossato, Helmut Glantschnig, Fabio Canneva, et al.
Thrombosis and Haemostasis|September 28, 2006
In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpuraRoberta Donadelli, Federica Banterla, Miriam Galbusera, et al.
Blood|May 14, 2005
ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseasesManfred Rieger, Pier Mannuccio Mannucci, Johanna A Kremer Hovinga, et al.
Blood|June 4, 2005
Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 casesFadi Fakhouri, Jean-Paul Vernant, Agnès Veyradier, et al.
Haematologica|April 21, 2022
Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell diseasePaolo Rossato, Enrica Federti, Alessandro Matte, et al.
Expert Review of Clinical Pharmacology|February 10, 2015
Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodesPeter L Turecek, Brigitt Abbühl, Srilatha D Tangada, et al.
Blood|December 18, 2014
Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humansChristoph J Hofbauer, Shawn F J Whelan, Maria Hirschler, et al.
European Journal of Pharmacology|December 24, 2017
Pharmacokinetics, disease-modifying activity, and safety of an experimental therapeutic targeting an immunological isoform of macrophage migration inhibitory factor, in rat glomerulonephritisWerner Höllriegl, Alexander Bauer, Bernhard Baumgartner, et al.
The Journal of Biological Chemistry|January 13, 2012
Neutralization of macrophage migration inhibitory factor (MIF) by fully human antibodies correlates with their specificity for the β-sheet structure of MIFRandolf J Kerschbaumer, Manfred Rieger, Dirk Völkel, et al.
Pageof 9